Smoking and vaporizing cannabis produced nearly identical blood cannabinoid levels, while edibles produced very different metabolite patterns, and researchers identified potential markers for recent use.
Read this if you want to understand how long cannabis stays detectable in blood and what science says about distinguishing recent from past use.
Detection windows under 8 hours using combined THC and metabolite ratio cutoffs across all consumption routes.
What the researchers found
Researchers gave the same dose of cannabis to both frequent and occasional users through three routes: smoking, vaporizing, and eating. They then tracked THC and its metabolites in blood for up to 72 hours.
Smoking and vaporizing produced remarkably similar blood cannabinoid patterns. Edibles, however, produced significantly higher levels of the metabolites THCCOOH and THCCOOH-glucuronide.
Two minor cannabinoids, cannabigerol (CBG) and cannabinol (CBN), appeared in blood only after inhaling cannabis and disappeared quickly, making them potential markers of recent use. They were not detected at all after oral consumption.
A combined cutoff of THC at or above 5 micrograms per liter plus a specific metabolite ratio produced detection windows under 8 hours for all consumption routes in frequent users.
Why it matters
Distinguishing recent cannabis use from past use is critical for DUI enforcement and workplace testing. Standard THC blood tests can show positive results for up to 30 days in frequent users, even when they are no longer impaired. This study provides evidence for biomarkers and cutoff combinations that narrow the detection window to hours rather than days.
The numbers in context
CBG and CBN were detected after inhalation with short detection windows but not after oral dosing. A combined THC greater than or equal to 5 micrograms per liter plus THCCOOH/11-OH-THC ratio less than 20 produced detection windows under 8 hours for all routes in frequent smokers. No occasional smoker tested positive 1.5 hours after inhalation or 12 hours after oral use with this cutoff.
How the study worked
This was a controlled, within-subject clinical trial. Participants received 50.6 mg of THC via smoking, vaporizing, or oral brownie across separate sessions. Blood was collected at multiple time points over 54 hours (occasional users) or 72 hours (frequent users). Researchers measured THC, its phase I and phase II metabolites, and minor cannabinoids using validated analytical methods.
What this study cannot tell us
The study used a single THC dose (50.6 mg). Real-world consumption varies widely in dose and potency. The sample size was relatively small. The proposed cutoffs need validation in larger populations and real-world settings before adoption in legal or workplace contexts.
How to read the evidence
Strong evidence from a controlled clinical trial with within-subject design comparing multiple administration routes using standardized doses.
When this study was published
Published in 2016. Cannabis products have become more potent since this study, which may affect detection windows.
The bigger picture
As cannabis legalization expands, law enforcement and employers need better tools to identify recent use rather than past use. This study establishes that vaping and smoking deliver THC equivalently, that edibles create a distinct metabolic signature, and that combining multiple biomarkers can narrow detection to recent consumption.
Questions still open
- Could CBG and CBN be used as roadside markers of recent cannabis inhalation? How do these pharmacokinetic profiles change with higher-potency products now common in legal markets? Would the proposed cutoffs work for people who use cannabis multiple times per day?
Common questions
Does vaping produce different blood THC levels than smoking?
Can a blood test tell if someone used cannabis recently versus days ago?
Read the original research
Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake.
Clinical chemistry, 62(12), 1579-1592
Citation
Newmeyer, Matthew N; Swortwood, Madeleine J; Barnes, Allan J; Abulseoud, Osama A; Scheidweiler, Karl B; Huestis, Marilyn A. (2016). Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake.. Clinical chemistry, 62(12), 1579-1592.
Explore the wider topic
- THC Purity and Potency: What the Label Actually Means
- Dab and Concentrate Withdrawal: Why It Hits Harder
- Delta-8 THC: Addiction, Withdrawal, and What We Don't Know
- Edible Addiction and Withdrawal: What Makes It Different
- Edibles and Psychosis: When a Bad Trip Becomes an Emergency
- Vaping vs Smoking vs Edibles: A Harm Reduction Guide
- How Cannabis Products Are Made: From Plant to Concentrate to Edible
- Laced Weed and Contaminated Vapes: Real Risks vs Myths
- Legal vs Street Weed: Quality, Safety, and What You're Actually Smoking
- Quitting Weed Pens and Dabs: Why Concentrates Hit Different
- Quitting Edibles: Is Withdrawal Different from Smoking?
- Sativa vs Indica: The Myth and the Science Behind Cannabis Strain Labels
- Why Is Weed Withdrawal Worse Now Than 20 Years Ago?
- Does Weed Expire? Shelf Life, Potency Loss, and Storage Science
- How to Store Weed So It Stays Fresh: Temperature, Light, and Humidity
- What Is Dabbing and What Does It Do to Your Body
- What Are Moon Rocks and Why Are They So Strong